Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7787393 | 0.83 | SMN1; SMN2 (0.44) | MAPTLMNASMN1; SMN2MAOB | |
| SCHEMBL7802510 | 0.83 | ALDH1A1 (0.38) | PDGFRBKITKDRMAP2K2MAP2K1 | |
| SCHEMBL7787383 | 0.81 | MAP2K1 (0.35) | MAPTLMNASMN1; SMN2MAOBPDGFRB | |
| SCHEMBL7784882 | 0.79 | KMT2A (0.38) | MAPTLMNAPDGFRBKITKDR | |
| SCHEMBL7787515 | 0.78 | LMNA (0.44) | MAPTLMNASMN1; SMN2MAOBCYP2C19 | |
| SCHEMBL7800363 | 0.78 | LMNA (0.37) | MAPTLMNAPDGFRBKITKDR | |
| SCHEMBL7787331 | 0.76 | CYP1A2 (0.44) | PDGFRBKITKDRCYP2C19 | |
| SCHEMBL7800376 | 0.75 | LMNA (0.34) | MAPTLMNAPDGFRBKITKDR | |
| SCHEMBL6036040 | 0.75 | MAPT (0.56) | MAPTLMNASMN1; SMN2MAOB | |
| SCHEMBL6035383 | 0.73 | LMNA (0.48) | MAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143957-A3 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-02-27 | — | — | EP | disclosed |
| EP-1143957-A2 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1140062-A2 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140067-A1 | ANTIVIRAL METHOD USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140046-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140291-A1 | COMBINATION CHEMOTHERAPY COMPRISING A MITOTIC INHIBITOR AND A MEK INHIBITOR | WARNER-LAMBERT COMPANY LLC (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035435-A9 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER LAMBERT CO (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-2000037141-A9 | COMBINATION CHEMOTHERAPY | WARNER LAMBERT CO (US) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000040237-A1 | ANTIVIRAL METHOD USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040235-A2 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000037141-A1 | COMBINATION CHEMOTHERAPY | WARNER-LAMBERT COMPANY (US) | 2000-06-29 | — | — | WO | disclosed |
| WO-2000035435-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035436-A2 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |